Investor Presentaiton

For personal use only Telix is pioneering a new cancer modality Kidney Cancer Glioblastoma Ph Name I/II IPAX-1 Breast Cancer Ph Name || Asset Dx/Tx TLX101 Tx Asset OPALESCENCE (IIT) TLX250-CDx Dx/Tx Dx Emory University (IIT) TLX591-CDx Dx Lung and Ovarian Cancers ......... TELIX PHARMACEUTICALS Ph Name Asset Dx/Tx III ZIRCON TLX250-CDx Dx I/II ZIRDAC TLX250-CDx Dx || STARLITE-1 (IIT) TLX250 Tx STARLITE-2+ (IIT) TLX250 Tx Prostate Cancer Ph Name Asset Dx/Tx Ph Name Asset Dx/Tx Royal Adelaide (IIT) APOMAB Dx/Tx Bone Marrow Conditioning Ph Name Asset Dx/Tx ||| || || || University of Linz (IIT) TLX591-CDx Dx Emory University (IIT) TLX591-CDx Dx ENHANCING (IIT) TLX591-CDx Dx Enzalutamide-Enhanced Imaging Mem. Sloan Kettering (IIT) TLX591-CDX Dx I/lla TRALA (IIT) TLX66 Tx N/A NOBLE TLX599-CDx Dx nobody left behind Bladder Cancer III Ph Name | ZIP-UP (IIT) | PERTINENCE (IIT) Asset Dx/Tx TLX250-CDx Dx TLX250-CDx Dx PROSTACT | CUPID *Registry study TLX591 Tx TLX592 Tx Telix Pharmaceuticals Limited (ASX: TLX) 19

View entire presentation